

Wright Medical Group, Inc.
Pro Forma Sales Growth Information
(unaudited)

First Quarter 2015
Pro Forma
Constant Currency Sales
Growth ⁽¹⁾

U.S.	
Foot and Ankle	19%
Upper Extremity	6%
Biologics	(2%)
Other	(54%)
Total U.S.	12%
International	
Foot and Ankle	5%
Upper Extremity	(22%)
Biologics	8%
Other	38%
Total International	5%
Global	
Foot and Ankle	15%
Upper Extremity	(6%)
Biologics	1%
Other	5%
Total Sales	10%

(1) Pro Forma Constant Currency Sales Growth is calculated as the growth of 2015 actual sales, excluding the impact of foreign currency over 2014 pro forma sales (as defined and reconciled below).

Wright Medical Group, Inc.
Pro Forma Same Day Sales Growth Information
(unaudited)

First Quarter 2015
Pro Forma
Same Day
Sales Growth ⁽¹⁾

U.S.	
Foot and Ankle	19%
Upper Extremity	6%
Biologics	(2%)
Other	(54%)
Total U.S.	12%

(1) Pro Forma Same Day Sales Growth is calculated as the growth of 2015 sales per selling day over 2014 pro forma sales (as defined and reconciled below) per selling day. We provide the number of U.S. selling days per quarter on our website at “Corporate - Investor Information - Financial Information - U.S. Selling Days.”

Wright Medical Group, Inc.
Pro Forma Sales
(unaudited)

	Q1 2014		
	As Reported	Acquired	Pro Forma
U.S.			
Foot and Ankle	33,127	2,041	35,168
Upper Extremity	3,653		3,653
Biologics	11,143	242	11,385
Other	1,028	34	1,062
Total U.S.	48,951	2,317	51,268
International			
Foot and Ankle	12,874		12,874
Upper Extremity	2,825		2,825
Biologics	4,497		4,497
Other	1,915		1,915
Total International	22,111		22,111
Global			
Foot and Ankle	46,001	2,041	48,042
Upper Extremity	6,478		6,478
Biologics	15,640	242	15,882
Other	2,943	34	2,977
Total Sales	71,062	2,317	73,379

(1) Pro Forma revenues are calculated from adding revenues recognized by Solana and OrthoPro prior to our acquisition of these businesses to our reported revenues in each respective period of 2014.

Wright Medical Group, Inc.
Reconciliation of Net Sales to Net Sales Excluding the Impact of Foreign Currency
(dollars in thousands--unaudited)

	Three Months Ended	
	March 31, 2015	
	International Net Sales	Total Net Sales
Net sales, as reported	\$ 20,448	\$ 77,934
Currency impact as compared to prior period	2,733	2,733
Net sales, excluding the impact of foreign currency	\$ 23,181	\$ 80,667

Wright Medical Group, Inc.
Reconciliation of As Reported Results to Non-GAAP Financial Measures
(in thousands, except per share data--unaudited)

	Three Months Ended	
	March 31, 2015	March 31, 2014
Operating Loss		
Operating loss, as reported	\$ (33,121)	\$ (23,046)
<i>Reconciling items impacting Gross Profit:</i>		
Inventory step-up amortization	28	604
Total	28	604
<i>Reconciling items impacting Selling, General and Administrative expense:</i>		
Distributor conversions	—	105
Due diligence, transaction and transition costs	11,024	7,402
Total	11,024	7,507
<i>Reconciling items impacting Amortization of Intangible Assets:</i>		
Amortization of distributor non-competes	24	437
Operating loss, as adjusted	\$ (22,045)	\$ (14,498)
Operating loss, as adjusted, as a percentage of net sales	(28.3)%	(20.4)%

Wright Medical Group, Inc.
Reconciliation of As Reported Results to Non-GAAP Financial Measures
(in thousands, except per share data--unaudited)

	Three Months Ended	
	March 31, 2015	March 31, 2014
EBITDA		
Net loss from continuing operations, as reported	\$ (46,248)	\$ (30,298)
Interest expense, net	7,649	4,136
Provision (benefit) for income taxes	166	(12,170)
Depreciation	5,280	4,241
Amortization of intangible assets	2,614	2,187
EBITDA	(30,539)	(31,904)
<i>Reconciling items impacting EBITDA</i>		
Non-cash stock-based compensation expense	2,337	2,320
Other expense, net	5,312	15,286
Inventory step-up amortization	28	604
Distributor conversions	—	105
Due diligence, transaction and transition costs	11,024	7,402
Adjusted EBITDA	\$ (11,838)	\$ (6,187)
Adjusted EBITDA as a percentage of net sales	(15.2)%	(8.7)%

Wright Medical Group, Inc.
Reconciliation of As Reported Results to Non-GAAP Financial Measures
(in thousands, except per share data--unaudited)

	Three Months Ended	
	March 31, 2015	March 31, 2014
Net Income		
Loss before taxes, as reported	\$ (46,082)	\$ (42,468)
<i>Pre-tax impact of reconciling items:</i>		
Inventory step-up amortization	28	604
Distributor conversion and non-competes	24	542
Non-cash interest expense on 2017 & 2020 Convertible Notes	4,457	2,259
Write-off of unamortized debt discount and deferred financing fees	25,201	—
Derivatives mark-to-market adjustment	(6,934)	1,000
Due diligence, transaction and transition costs	11,024	7,402
CVR mark-to-market adjustments	(13,454)	14,295
Loss before taxes, as adjusted	(25,736)	(16,366)
Provision (benefit) for income taxes, as reported	\$ 166	\$ (12,170)
U.S. tax impact resulting from gain in discontinued operations	—	12,362
Provision (benefit) for income taxes, as adjusted	\$ 166	\$ 192
Effective tax rate, as adjusted	(0.6)%	(1.2)%
Net loss, as adjusted	\$ (25,902)	\$ (16,558)
Weighted-average number of shares outstanding-diluted	50,868	48,625
Net loss from continuing operations, as adjusted, per diluted share	\$ (0.51)	\$ (0.34)

Wright Medical Group, Inc.
Reconciliation of Free Cash Flow
(dollars in thousands--unaudited)

	Three Months Ended	
	March 31, 2015	March 31, 2014
Net cash used in operating activities	\$ (25,246)	\$ (27,240)
Capital expenditures	(11,854)	(7,836)
Free cash flow	\$ (37,100)	\$ (35,076)